12:00 AM
Jun 02, 2003
 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch

Date Company Staff cuts Notes Current cash Cash reporting date Operating loss Op loss period
5/29/03 Allos (ALTH) 34% to61 Suspended development of BGP-15, a chemoprotectant in preclinical development. Expects to reduce its quarterly cash burn to $6-$7 million. $49.1 3/31 $7.5 1Q ended 3/31
5/15/03 AltaRex (TSE: AXO; ALXFF) (A) (B) Not disclosed Laying off undisclosed number of employees. President and...

Read the full 422 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >